Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.
Neijssen J, Cardoso RMF, Chevalier KM, Wiegman L, Valerius T, Anderson GM, Moores SL, Schuurman J, Parren PWHI, Strohl WR, Chiu ML. Neijssen J, et al. Among authors: chevalier km. J Biol Chem. 2021 Jan-Jun;296:100641. doi: 10.1016/j.jbc.2021.100641. Epub 2021 Apr 8. J Biol Chem. 2021. PMID: 33839159 Free PMC article.
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis.
Vijayaraghavan S, Lipfert L, Chevalier K, Bushey BS, Henley B, Lenhart R, Sendecki J, Beqiri M, Millar HJ, Packman K, Lorenzi MV, Laquerre S, Moores SL. Vijayaraghavan S, et al. Mol Cancer Ther. 2020 Oct;19(10):2044-2056. doi: 10.1158/1535-7163.MCT-20-0071. Epub 2020 Aug 3. Mol Cancer Ther. 2020. PMID: 32747419
Pharmacologic Characterization of JNJ-42226314, [1-(4-Fluorophenyl)indol-5-yl]-[3-[4-(thiazole-2-carbonyl)piperazin-1-yl]azetidin-1-yl]methanone, a Reversible, Selective, and Potent Monoacylglycerol Lipase Inhibitor.
Wyatt RM, Fraser I, Welty N, Lord B, Wennerholm M, Sutton S, Ameriks MK, Dugovic C, Yun S, White A, Nguyen L, Koudriakova T, Tian G, Suarez J, Szewczuk L, Bonnette W, Ahn K, Ghosh B, Flores CM, Connolly PJ, Zhu B, Macielag MJ, Brandt MR, Chevalier K, Zhang SP, Lovenberg T, Bonaventure P. Wyatt RM, et al. J Pharmacol Exp Ther. 2020 Mar;372(3):339-353. doi: 10.1124/jpet.119.262139. Epub 2019 Dec 9. J Pharmacol Exp Ther. 2020. PMID: 31818916
Diabetogenic effect of a series of tricyclic delta opioid agonists structurally related to cyproheptadine.
Codd EE, Baker J, Brandt MR, Bryant S, Cai C, Carson JR, Chevalier KM, Colburn RW, Coogan TP, Dax SL, Decorte B, Kemmerer M, Legrand EK, Lenhard JM, Leone AM, Lin L, Mabus JR, McDonnell ME, McMillian MK, McNally JJ, Stone DJ Jr, Wang CY, Zhang SP, Flores CM. Codd EE, et al. Among authors: chevalier km. Toxicol Sci. 2010 Oct;117(2):493-504. doi: 10.1093/toxsci/kfq200. Epub 2010 Jul 8. Toxicol Sci. 2010. PMID: 20616206
13 results